A 31-year-old G2P1001 presents to the labor floor for external cephalic version (ECV) due to breech presentation at 37 weeks gestation. Her pregnancy has been complicated by an episode of pyelonephritis at 14 weeks gestation, treated with intravenous ceftriaxone. The patient has not had urinary symptoms since that time. Otherwise, her prenatal care has been routine and she tested Rh-negative with negative antibodies at her first prenatal visit. She has a history of one prior spontaneous vaginal delivery without complications. She also has a medical history of anemia. Current medications include nitrofurantoin for urinary tract infection suppression and iron supplementation. The patient’s temperature is 98.5°F (36.9°C), pulse is 75/min, blood pressure is 122/76 mmHg, and respirations are 13/min. Physical exam is notable for a fundal height of 37 centimeters and mild pitting edema in both lower extremities. Cardiopulmonary exams are unremarkable. Bedside ultrasound confirms that the fetus is still in breech presentation. Which of the following should be performed in this patient as a result of her upcoming external cephalic version?
Q52
A 15-year-old girl is brought to the clinic by her mother for an annual well-exam. She is relatively healthy with an unremarkable birth history. She reports no specific concerns except for the fact that her friends “already got their periods and I still haven’t gotten mine.” Her mom reports that she also had her menarche late and told her not to worry. When alone, the patient denies any pain, fevers, weight changes, vaginal discharge, or psychosocial stressors. Physical examination demonstrates a healthy female with a Tanner 4 stage of development of breast, genitalia, and pubic hair. What findings would you expect in this patient?
Q53
A 54-year-old woman comes to the office complaining of increased urinary frequency and dysuria. She is accompanied by her husband. The patient reports that she goes to the bathroom 6-8 times a day. Additionally, she complains of pain at the end of her urinary stream. She denies fever, abdominal pain, vaginal discharge, or hematuria. Her husband adds, “we also don’t have sex as much as we used to.” The patient reports that even when she is “in the mood,” sex is “no longer pleasurable.” She admits feeling guilty about this. The patient’s last menstrual period was 15 months ago. Her medical history is significant for hyperlipidemia and coronary artery disease. She had a non-ST elevation myocardial infarction (NSTEMI) 3 months ago, and she has had multiple urinary tract infections (UTIs) in the past year. She smokes 1 pack of cigarettes a day and denies alcohol or illicit drug use. Body mass index is 32 kg/m^2. Pelvic examination reveals vaginal dryness and vulvar tissue thinning. A urinalysis is obtained as shown below:
Urinalysis
Glucose: Negative
WBC: 25/hpf
Bacterial: Many
Leukocyte esterase: Positive
Nitrites: Positive
The patient is prescribed a 5-day course of nitrofurantoin. Which of the following is the most appropriate additional management for the patient’s symptoms?
Q54
A 27-year-old G1P0 at 12 weeks gestation presents to her obstetrician for her first prenatal visit. She and her husband both have achondroplasia, and she is curious what are the chances that they will have a child of average height. What percent of pregnancies between two individuals with achondroplasia that result in a live birth will be expected to be offspring that are unaffected by this condition?
Q55
A 16-year-old girl comes to the physician for a regular health visit. She feels healthy. She lives with her parents at home. She says that the relationship with her parents has been strained lately because they ""do not approve"" of her new boyfriend. She recently became sexually active with her boyfriend and requests a prescription for an oral contraception. She does not want her parents to know. She smokes half-a-pack of cigarettes per day and does not drink alcohol. She appears well-nourished. Physical examination shows no abnormalities. Urine pregnancy test is negative. Which of the following is the most appropriate next step in management?
Q56
A 29-year-old G1P0 female at 32 weeks gestation presents to the emergency department with vaginal bleeding. She has had minimal prenatal care to-date with only an initial visit with an obstetrician after a positive home pregnancy test. She describes minimal spotting that she noticed earlier today that has progressed to larger amounts of blood; she estimates 30 mL of blood loss. She denies any cramping, pain, or contractions, and she reports feeling continued movements of the baby. Ultrasound and fetal heart rate monitoring confirm the presence of a healthy fetus without any evidence of current or impending complications. The consulted obstetrician orders blood testing for Rh-status of both the mother as well as the father, who brought the patient to the hospital. Which of the following represents the best management strategy for this situation?
Q57
A 27-year-old woman comes to the physician because of a 1-month history of progressive shortness of breath. She can no longer walk one block without stopping to catch her breath. Her last menstrual period was 3 months ago. Menarche occurred at the age of 12 years, and menses had occurred at regular 28-day intervals. Cardiac examination shows a grade 3/6, rumbling diastolic murmur at the apex. Laboratory studies show an elevated β-hCG concentration. Which of the following is the most likely explanation for this patient's worsening dyspnea?
Q58
A 21-year-old woman, gravida 1, para 0, at 39 weeks' gestation comes to the physician for a prenatal visit. She has some mild edema and tiredness but generally feels well. She recently had a nephew visiting for 1 week who became ill and was diagnosed with the chickenpox. She has no history of chickenpox and is not vaccinated against the varicella zoster virus. Current medications include folic acid supplements and a prenatal vitamin. Her temperature is 37°C (98.6°F), pulse is 82/min, respirations are 15/min, and blood pressure is 116/64 mm Hg. Pelvic examination shows a uterus consistent in size with 39 weeks' gestation. IgG antibody titers for varicella zoster virus are negative. Which of the following is the most appropriate next step in management?
Q59
A 26-year-old G1P0 woman presents for her first prenatal visit. Past medical history reveals the patient is blood type O negative, and the father is type A positive. The patient refuses Rho(D) immune globulin (RhoGAM), because it is derived from human plasma, and she says she doesn’t want to take the risk of contracting HIV. Which of the following is correct regarding the potential condition her baby may develop?
Q60
An otherwise healthy 18-year-old girl comes to the physician because of a 1-year history of severe acne vulgaris over her face, upper back, and arms. Treatment with oral antibiotics and topical combination therapy with benzoyl peroxide and retinoid has not completely resolved her symptoms. Examination shows oily skin with numerous comedones, pustules, and scarring over the face and upper back. Long-term therapy is started with combined oral contraceptives. This medication significantly reduces the risk of developing which of the following conditions?
Prenatal Care US Medical PG Practice Questions and MCQs
Question 51: A 31-year-old G2P1001 presents to the labor floor for external cephalic version (ECV) due to breech presentation at 37 weeks gestation. Her pregnancy has been complicated by an episode of pyelonephritis at 14 weeks gestation, treated with intravenous ceftriaxone. The patient has not had urinary symptoms since that time. Otherwise, her prenatal care has been routine and she tested Rh-negative with negative antibodies at her first prenatal visit. She has a history of one prior spontaneous vaginal delivery without complications. She also has a medical history of anemia. Current medications include nitrofurantoin for urinary tract infection suppression and iron supplementation. The patient’s temperature is 98.5°F (36.9°C), pulse is 75/min, blood pressure is 122/76 mmHg, and respirations are 13/min. Physical exam is notable for a fundal height of 37 centimeters and mild pitting edema in both lower extremities. Cardiopulmonary exams are unremarkable. Bedside ultrasound confirms that the fetus is still in breech presentation. Which of the following should be performed in this patient as a result of her upcoming external cephalic version?
A. Fibrinogen level
B. Urinalysis
C. Urine protein to creatinine ratio
D. Complete blood count
E. Rhogam administration (Correct Answer)
Explanation: ***Rhogam administration***
- An **external cephalic version (ECV)** carries a risk of **fetal-maternal hemorrhage** due to manipulation of the uterus and fetus.
- For **Rh-negative mothers**, Rhogam (anti-D immune globulin) administration is crucial to prevent **Rh alloimmunization** if fetal blood enters maternal circulation.
*Fibrinogen level*
- A fibrinogen level is typically checked in cases of suspected **disseminated intravascular coagulation (DIC)** or significant bleeding risk, such as in patients with **placental abruption** or severe pre-eclampsia.
- While bleeding is a potential complication of any obstetric procedure, routine fibrinogen levels are not indicated prior to an ECV in an otherwise healthy patient with no signs of bleeding dyscrasia.
*Urinalysis*
- Although the patient has a history of pyelonephritis and is on nitrofurantoin, she has been **asymptomatic** and a urinalysis was likely performed recently as part of her routine prenatal care.
- While urinary tract infections can be a concern in pregnancy, a urinalysis is not a direct requirement for an ECV unless new urinary symptoms arise.
*Urine protein to creatinine ratio*
- A urine protein to creatinine ratio is used to screen for or confirm **preeclampsia**, a condition characterized by **hypertension and proteinuria**.
- The patient's blood pressure is normal (122/76 mmHg) and there is no mention of proteinuria, so this test is not indicated for the ECV.
*Complete blood count*
- While a complete blood count (CBC) would confirm her known anemia and assess for infection, it is **not directly necessitated by the ECV procedure itself** as a preventive measure against Rh incompatibility.
- The primary concern for an Rh-negative mother undergoing ECV is feto-maternal hemorrhage, making Rhogam the critical intervention.
Question 52: A 15-year-old girl is brought to the clinic by her mother for an annual well-exam. She is relatively healthy with an unremarkable birth history. She reports no specific concerns except for the fact that her friends “already got their periods and I still haven’t gotten mine.” Her mom reports that she also had her menarche late and told her not to worry. When alone, the patient denies any pain, fevers, weight changes, vaginal discharge, or psychosocial stressors. Physical examination demonstrates a healthy female with a Tanner 4 stage of development of breast, genitalia, and pubic hair. What findings would you expect in this patient?
A. Formation of breast mound
B. Flat chest with raised nipples
C. Formation of breast bud
D. Raised areola
E. Coarse hair across pubis and medial thigh (Correct Answer)
Explanation: ***Coarse hair across pubis and medial thigh***
- A healthy 15-year-old girl with **Tanner 4 stage development** of pubic hair will exhibit adult-type hair that is **coarse, curly, and abundant**, extending over the mons pubis and spreading to the medial thighs.
- This stage indicates near-complete sexual maturation in terms of pubic hair growth, consistent with a patient who has developed secondary sexual characteristics but has not yet experienced menarche.
*Formation of breast mound*
- The **formation of a breast mound** is characteristic of Tanner Stage 4 breast development where the areola and papilla form a secondary mound above the general contour of the breast, which is consistent with the patient's overall Tanner 4 stage development.
- However, the question asks specifically about findings in a healthy 15-year-old with Tanner 4 development across **all categories (breast, genitalia, pubic hair)**, not just the breasts. The correct answer focuses on the specific visual changes of the pubic hair itself at this stage.
*Flat chest with raised nipples*
- A **flat chest with raised nipples** (nipple elevation) describes Tanner Stage 2 breast development, which is an earlier stage than the patient's reported Tanner Stage 4.
- This stage precedes significant breast enlargement and the development of a distinct breast mound.
*Formation of breast bud*
- The **formation of a breast bud** (small, tender lump under the nipple) is the defining characteristic of Tanner Stage 2 breast development, indicating the very beginning of breast growth.
- This is an earlier stage than the Tanner Stage 4 described for this patient.
*Raised areola*
- **Raised areola** with a flattened breast contour is characteristic of Tanner Stage 3 breast development, where the breast and areola enlarge further, but the areola typically lies on the same contour as the breast.
- In Tanner Stage 4, the areola and papilla elevate above the general breast contour, forming a secondary mound.
Question 53: A 54-year-old woman comes to the office complaining of increased urinary frequency and dysuria. She is accompanied by her husband. The patient reports that she goes to the bathroom 6-8 times a day. Additionally, she complains of pain at the end of her urinary stream. She denies fever, abdominal pain, vaginal discharge, or hematuria. Her husband adds, “we also don’t have sex as much as we used to.” The patient reports that even when she is “in the mood,” sex is “no longer pleasurable.” She admits feeling guilty about this. The patient’s last menstrual period was 15 months ago. Her medical history is significant for hyperlipidemia and coronary artery disease. She had a non-ST elevation myocardial infarction (NSTEMI) 3 months ago, and she has had multiple urinary tract infections (UTIs) in the past year. She smokes 1 pack of cigarettes a day and denies alcohol or illicit drug use. Body mass index is 32 kg/m^2. Pelvic examination reveals vaginal dryness and vulvar tissue thinning. A urinalysis is obtained as shown below:
Urinalysis
Glucose: Negative
WBC: 25/hpf
Bacterial: Many
Leukocyte esterase: Positive
Nitrites: Positive
The patient is prescribed a 5-day course of nitrofurantoin. Which of the following is the most appropriate additional management for the patient’s symptoms?
A. Venlafaxine
B. Antibiotic prophylaxis
C. Combination oral contraceptives
D. Topical clobetasol
E. Topical estrogen (Correct Answer)
Explanation: ***Topical estrogen***
- The patient's symptoms of **vaginal dryness**, **dyspareunia**, **recurrent UTIs**, and **urinary frequency** are highly suggestive of **genitourinary syndrome of menopause (GSM)**, previously known as vulvovaginal atrophy. Vaginal examination findings of **vaginal tissue thinning** further support this diagnosis.
- **Topical estrogen** directly addresses the underlying **estrogen deficiency**, restoring vaginal and urethral tissue health, thereby alleviating both sexual and urinary symptoms. Given her history of CAD and an NSTEMI, topical estrogen is preferred over systemic estrogen due to its minimal systemic absorption.
*Venlafaxine*
- **Venlafaxine** is a serotonin-norepinephrine reuptake inhibitor (SNRI) that can be used to treat **vasomotor symptoms of menopause** (e.g., hot flashes) or depression.
- It does not directly address the **urogenital symptoms of GSM** such as vaginal dryness, dyspareunia, or recurrent UTIs, and therefore would not be the most appropriate primary treatment for these specific complaints.
*Antibiotic prophylaxis*
- While the patient experiences **recurrent UTIs**, treating the underlying cause of these infections, which is likely **vaginal atrophy** due to menopause, should be prioritized.
- **Antibiotic prophylaxis** would only temporarily prevent infections without addressing the fundamental tissue changes that predispose her to UTIs.
*Combination oral contraceptives*
- **Combination oral contraceptives** contain both estrogen and progestin, but they are primarily used for contraception and often to manage **perimenopausal symptoms** in younger women.
- They are generally contraindicated in women over 35 who smoke or have a history of CAD due to increased risk of thrombotic events, and are not the primary treatment for **urogenital atrophy** in postmenopausal women, especially with her clinical history.
*Topical clobetasol*
- **Topical clobetasol** is a high-potency corticosteroid used to treat inflammatory dermatoses, such as **lichen sclerosus** or severe eczema.
- It would not be appropriate for treating **vaginal dryness**, **dyspareunia**, or **recurrent UTIs** caused by **estrogen deficiency**, and its prolonged use can lead to skin atrophy.
Question 54: A 27-year-old G1P0 at 12 weeks gestation presents to her obstetrician for her first prenatal visit. She and her husband both have achondroplasia, and she is curious what are the chances that they will have a child of average height. What percent of pregnancies between two individuals with achondroplasia that result in a live birth will be expected to be offspring that are unaffected by this condition?
A. 0%
B. 50%
C. 75%
D. 33% (Correct Answer)
E. 25%
Explanation: ***33%***
- Achondroplasia is an **autosomal dominant** condition, meaning only one copy of the mutated gene is needed to express the trait. However, individuals with achondroplasia are typically **heterozygous (Aa)** because the homozygous dominant state (AA) is **lethal in utero** or shortly after birth.
- When two heterozygous (Aa) parents mate, a Punnett square shows 25% AA, 50% Aa, and 25% aa. Since AA is a lethal genotype that is not viable for live birth, the surviving offspring will be 1/3 aa (unaffected) and 2/3 Aa (affected), meaning 33% will be of average height.
*0%*
- This would be true if all offspring were affected or if the condition was recessive and both parents were homozygous dominant, which is not the case for achondroplasia.
- The possibility of having an unaffected child exists because affected individuals are generally heterozygous.
*50%*
- This would be the percentage of affected offspring if one parent was homozygous dominant and the other was homozygous recessive, or if one parent was homozygous dominant and the other heterozygous.
- However, autosomal dominant traits typically result in a 2:1 ratio of affected to unaffected live births when both parents are heterozygous.
*75%*
- This would be the percentage of affected offspring if the homozygous dominant state were not lethal, resulting in 25% aa, 50% Aa, and 25% AA.
- Achondroplasia, however, has a **lethal homozygous dominant genotype**, which alters the observed phenotypic ratios in live births.
*25%*
- This percentage represents the chance of having an unaffected offspring (aa) before considering the lethality of the homozygous dominant genotype (AA).
- When accounting for the non-viability of AA genotypes, the proportion of unaffected offspring among live births increases.
Question 55: A 16-year-old girl comes to the physician for a regular health visit. She feels healthy. She lives with her parents at home. She says that the relationship with her parents has been strained lately because they ""do not approve"" of her new boyfriend. She recently became sexually active with her boyfriend and requests a prescription for an oral contraception. She does not want her parents to know. She smokes half-a-pack of cigarettes per day and does not drink alcohol. She appears well-nourished. Physical examination shows no abnormalities. Urine pregnancy test is negative. Which of the following is the most appropriate next step in management?
A. Recommend an oral contraceptive pill
B. Discuss all effective contraceptive options (Correct Answer)
C. Conduct HIV screening
D. Inform patient that her smoking history disqualifies her for oral contraceptives
E. Ask patient to obtain parental consent before discussing any contraceptive options
Explanation: ***Discuss all effective contraceptive options***
- It is crucial to discuss all available and **effective contraceptive options** with the patient, including their benefits, risks, and suitability for her lifestyle, before recommending a specific method.
- This ensures **informed consent** and shared decision-making, empowering the patient to choose the best method for her needs.
*Recommend an oral contraceptive pill*
- Recommending only one method without discussing alternatives limits the patient's choices and does not provide a **comprehensive approach** to contraception.
- While oral contraceptives are effective, other methods like **long-acting reversible contraceptives (LARCs)** may be more suitable or preferred by the patient.
*Conduct HIV screening*
- While **HIV screening** is important for sexually active individuals, it is not the immediate next step in management when the patient's primary concern is contraception.
- Addressing the patient's immediate request for contraception takes precedence, though **STI/HIV counseling** should be part of comprehensive sexual health discussions.
*Inform patient that her smoking history disqualifies her for oral contraceptives*
- A smoking history in adolescent patients **does not automatically disqualify** them from all types of oral contraceptives, especially progestin-only pills.
- The risk of **thromboembolism** with combined oral contraceptives is increased in smokers over 35, but a 16-year-old's risk needs careful assessment and discussion, not an outright disqualification.
*Ask patient to obtain parental consent before discussing any contraceptive options*
- In many jurisdictions, including the US, minors have the right to **confidential reproductive healthcare services**, including contraception, without parental consent.
- Requiring parental consent would violate her **confidentiality rights** and could deter her from seeking necessary care, potentially leading to unintended pregnancy.
Question 56: A 29-year-old G1P0 female at 32 weeks gestation presents to the emergency department with vaginal bleeding. She has had minimal prenatal care to-date with only an initial visit with an obstetrician after a positive home pregnancy test. She describes minimal spotting that she noticed earlier today that has progressed to larger amounts of blood; she estimates 30 mL of blood loss. She denies any cramping, pain, or contractions, and she reports feeling continued movements of the baby. Ultrasound and fetal heart rate monitoring confirm the presence of a healthy fetus without any evidence of current or impending complications. The consulted obstetrician orders blood testing for Rh-status of both the mother as well as the father, who brought the patient to the hospital. Which of the following represents the best management strategy for this situation?
A. After 28 weeks gestation, administration of RhoGAM will have no benefit
B. If mother is Rh-positive and father is Rh-negative then administer RhoGAM
C. If mother is Rh-negative and father is Rh-negative then administer RhoGAM
D. If mother is Rh-negative and father is Rh-positive, RhoGAM administration is not needed
E. If mother is Rh-negative and father is Rh-positive then administer RhoGAM (Correct Answer)
Explanation: ***If mother is Rh-negative and father is Rh-positive then administer RhoGAM***
- This combination creates a risk for **Rh incompatibility**, meaning the fetus could be Rh-positive and the mother's immune system could form antibodies against fetal red blood cells, which can harm the fetus in future pregnancies.
- **RhoGAM (Rh immunoglobulin)** administration prevents the mother from forming these antibodies when there's a risk of maternal-fetal blood mixing, as indicated by vaginal bleeding.
*After 28 weeks gestation, administration of RhoGAM will have no benefit*
- This statement is incorrect; **RhoGAM is routinely administered around 28 weeks gestation** as prophylaxis in Rh-negative mothers, even without bleeding episodes, to prevent sensitization.
- In cases of potential fetal-maternal hemorrhage, such as vaginal bleeding, RhoGAM is indicated regardless of gestational age beyond the first trimester.
*If mother is Rh-positive and father is Rh-negative then administer RhoGAM*
- This scenario does not pose a risk for **Rh incompatibility hemolytic disease of the newborn**, as the mother already possesses the Rh antigen.
- RhoGAM is specifically given to Rh-negative mothers to prevent their immune system from reacting to an Rh-positive fetus.
*If mother is Rh-negative and father is Rh-negative then administer RhoGAM*
- In this case, both parents are **Rh-negative**, meaning the fetus will also be Rh-negative.
- There is no risk of **Rh incompatibility** or sensitization, so RhoGAM administration is not indicated.
*If mother is Rh-negative and father is Rh-positive, RhoGAM administration is not needed*
- This statement is incorrect and represents a critical misunderstanding of **Rh incompatibility prophylaxis**.
- This specific genetic combination creates the highest risk for **Rh sensitization** during pregnancy, especially with events like vaginal bleeding, making RhoGAM administration essential.
Question 57: A 27-year-old woman comes to the physician because of a 1-month history of progressive shortness of breath. She can no longer walk one block without stopping to catch her breath. Her last menstrual period was 3 months ago. Menarche occurred at the age of 12 years, and menses had occurred at regular 28-day intervals. Cardiac examination shows a grade 3/6, rumbling diastolic murmur at the apex. Laboratory studies show an elevated β-hCG concentration. Which of the following is the most likely explanation for this patient's worsening dyspnea?
A. Decreased minute ventilation
B. Increased peripheral vascular resistance
C. Increased right ventricular afterload
D. Increased intravascular volume (Correct Answer)
E. Decreased right ventricular preload
Explanation: ***Increased intravascular volume***
- Pregnancy causes a significant **increase in plasma volume** (up to 50%) and **cardiac output**, which can exacerbate pre-existing cardiac conditions like mitral stenosis.
- The elevated intravascular volume leads to increased pressure in the **left atrium** and **pulmonary circulation**, causing pulmonary congestion and dyspnea.
*Decreased minute ventilation*
- **Minute ventilation** actually increases during pregnancy due to increased tidal volume and respiratory rate to meet higher oxygen demands.
- A *decrease* in minute ventilation would lead to **hypercapnia** and respiratory acidosis, which is not consistent with the typical presentation of worsening dyspnea in pregnancy-exacerbated mitral stenosis.
*Increased peripheral vascular resistance*
- Pregnancy is associated with a **decrease in systemic vascular resistance (SVR)**, primarily due to the effects of progesterone and the low-resistance placental circulation.
- An *increase* in SVR would typically lead to increased **afterload** on the left ventricle and hypertension, which is not the primary mechanism for dyspnea in this context.
*Increased right ventricular afterload*
- While **pulmonary hypertension** can increase right ventricular afterload in severe mitral stenosis, the primary hemodynamic stressor in pregnancy is the **volume overload**.
- The *initial* and most direct impact of increased intravascular volume leading to dyspnea is on the left heart and pulmonary circulation, not primarily increased right ventricular afterload.
*Decreased right ventricular preload*
- **Right ventricular preload** generally increases in pregnancy due to the elevated blood volume, reflecting increased venous return to the heart.
- A *decrease* in right ventricular preload would typically lead to reduced cardiac output and hypotension, rather than exacerbated dyspnea from pulmonary congestion.
Question 58: A 21-year-old woman, gravida 1, para 0, at 39 weeks' gestation comes to the physician for a prenatal visit. She has some mild edema and tiredness but generally feels well. She recently had a nephew visiting for 1 week who became ill and was diagnosed with the chickenpox. She has no history of chickenpox and is not vaccinated against the varicella zoster virus. Current medications include folic acid supplements and a prenatal vitamin. Her temperature is 37°C (98.6°F), pulse is 82/min, respirations are 15/min, and blood pressure is 116/64 mm Hg. Pelvic examination shows a uterus consistent in size with 39 weeks' gestation. IgG antibody titers for varicella zoster virus are negative. Which of the following is the most appropriate next step in management?
A. Reassurance
B. Serial ultrasounds
C. Varicella vaccine
D. Varicella zoster immune globulin (Correct Answer)
E. Ganciclovir therapy
Explanation: ***Varicella zoster immune globulin***
- The patient has been exposed to **chickenpox** (via her nephew), has no history of the disease, and is **not vaccinated**, indicating she is susceptible. Her negative **IgG antibody titers** confirm her lack of immunity.
- Due to her **39 weeks' gestation**, there is a risk of severe maternal varicella and congenital varicella syndrome, making **varicella zoster immune globulin (VZIG)** an appropriate post-exposure prophylaxis to mitigate the severity of infection.
*Reassurance*
- Reassurance alone is insufficient given the patient's **non-immune status** and recent **exposure to varicella**, which places her and the fetus at risk.
- Varicella infection during pregnancy can lead to serious complications, including **congenital varicella syndrome** or **neonatal varicella**.
*Serial ultrasounds*
- While ultrasounds may be used to monitor for fetal complications if **maternal infection** occurs, they are not a prophylactic measure to prevent or reduce the severity of the infection itself.
- The immediate priority is to prevent or attenuate the infection after exposure in a **non-immune pregnant woman**.
*Varicella vaccine*
- The **live attenuated varicella vaccine** is **contraindicated** during pregnancy due to the theoretical risk of fetal infection.
- Vaccination should ideally occur **before pregnancy** or postpartum.
*Ganciclovir therapy*
- **Ganciclovir** is an antiviral medication primarily used for **cytomegalovirus (CMV)** infections and is generally not the first-line treatment for varicella, especially in a prophylactic setting.
- For varicella, **acyclovir** or **valacyclovir** might be considered for treatment of active infection, but VZIG is the recommended post-exposure prophylaxis in non-immune pregnant women.
Question 59: A 26-year-old G1P0 woman presents for her first prenatal visit. Past medical history reveals the patient is blood type O negative, and the father is type A positive. The patient refuses Rho(D) immune globulin (RhoGAM), because it is derived from human plasma, and she says she doesn’t want to take the risk of contracting HIV. Which of the following is correct regarding the potential condition her baby may develop?
A. The injection can be avoided because the risk of complications of this condition is minimal
B. She should receive Rho(D) immune globulin to prevent the development of Rh(D) alloimmunization (Correct Answer)
C. The Rho(D) immune globulin will also protect the baby against other Rh antigens aside from Rh(D)
D. She should receive Rho(D) immune globulin to prevent the development of ABO incompatibility
E. Rho(D) immune globulin is needed both before and immediately after delivery to prevent maternal sensitization for future pregnancies
Explanation: ***She should receive Rho(D) immune globulin to prevent the development of Rh(D) alloimmunization***
- The patient is **Rh-negative** and her partner is **Rh-positive**, creating a risk for **Rh incompatibility** where the mother can develop antibodies against fetal Rh-positive red blood cells.
- **Rho(D) immune globulin** prevents the mother from becoming sensitized to the **Rh(D) antigen** if fetal blood enters her circulation, thus preventing **hemolytic disease of the newborn** in this or future pregnancies.
*The injection can be avoided because the risk of complications of this condition is minimal*
- This statement is incorrect; **Rh alloimmunization** can lead to severe consequences for the fetus, including **hemolytic disease of the newborn**, which can cause **fetal hydrops**, severe anemia, and even death.
- The risk of complications is not minimal, and prevention with **Rho(D) immune globulin** is a standard and critical part of prenatal care for Rh-negative mothers.
*The Rho(D) immune globulin will also protect the baby against other Rh antigens aside from Rh(D)*
- **Rho(D) immune globulin** is specifically formulated to target the **Rh(D) antigen** and will not protect against alloimmunization to other **Rh antigens** (e.g., C, c, E, e).
- While other Rh antigens can cause incompatibility, the **D antigen** is by far the most immunogenic and clinically significant.
*She should receive Rho(D) immune globulin to prevent the development of ABO incompatibility*
- **ABO incompatibility** is a different condition that can occur when the mother is **type O** and the baby is type A or B (as is the case here with an A-positive father), but it is generally **less severe** than Rh incompatibility and usually does not require **Rho(D) immune globulin** for prevention.
- **Rho(D) immune globulin** specifically targets the **Rh(D) antigen** and plays no role in preventing or treating **ABO incompatibility**.
*Rho(D) immune globulin is needed both before and immediately after delivery to prevent maternal sensitization for future pregnancies*
- For **Rh-negative** mothers, **Rho(D) immune globulin** is administered around **28 weeks of gestation** and again within **72 hours after delivery** if the baby is Rh-positive.
- This dual administration strategy covers potential fetal-maternal hemorrhages during pregnancy and at birth, but it's not "both before and immediately after delivery" as a blanket statement for *all* exposures; the prenatal dose is crucial.
Question 60: An otherwise healthy 18-year-old girl comes to the physician because of a 1-year history of severe acne vulgaris over her face, upper back, and arms. Treatment with oral antibiotics and topical combination therapy with benzoyl peroxide and retinoid has not completely resolved her symptoms. Examination shows oily skin with numerous comedones, pustules, and scarring over the face and upper back. Long-term therapy is started with combined oral contraceptives. This medication significantly reduces the risk of developing which of the following conditions?
A. Endometrial cancer (Correct Answer)
B. Hepatic adenoma
C. Hypertension
D. Malignant melanoma
E. Deep vein thrombosis
Explanation: ***Endometrial cancer***
- Combined oral contraceptives (COCs) reduce the risk of **endometrial cancer** by suppressing chronic **estrogen-induced endometrial proliferation** through progesterone's anti-proliferative effects.
- The protective effect increases with the **duration of COC use** and persists for several years after discontinuation.
*Hepatic adenoma*
- **Hepatic adenomas** are a recognized, though rare, complication of combined oral contraceptive use.
- The risk increases with **higher estrogen doses** and **longer duration of use**.
*Hypertension*
- COCs can cause a **slight increase in blood pressure** in some women, particularly due to the estrogen component, and are therefore a risk factor for hypertension, not protective against it.
- This effect is generally mild, but blood pressure monitoring is recommended for women on COCs.
*Malignant melanoma*
- There is **no clear evidence** that combined oral contraceptives significantly reduce the risk of malignant melanoma.
- Some studies have suggested a possible *increased risk* or no association, but protective effects are not established.
*Deep vein thrombosis*
- COCs, especially those containing higher estrogen doses, are associated with an **increased risk of deep vein thrombosis (DVT)** due to their effects on coagulation factors.
- This is a well-known adverse effect, not a condition prevented by COC use.